Pharmacovigilance profiles of three generations of mineralocorticoid receptor antagonists and network toxicology analysis
By
Hai-Hong Lin
Wen-Hui Cui
Feng Xu
Jia-Yi He
Liu-Cheng Li
Jun-Jie Xu
Xin Jiang
Kai-Li Mao
June 23, 2026
Clinical Scorecard: Comparative Analysis of Post-Marketing Safety Profiles for Three Generations of Mineralocorticoid Receptor Antagonists and Network Toxicology Assessment
At a Glance
Category Detail
Condition Mineralocorticoid receptor antagonists safety profiles Key Mechanisms Aldosterone-regulated sodium reabsorption, MAPK signaling Target Population Patients with cardiovascular and renal disorders Care Setting Clinical settings utilizing mineralocorticoid receptor antagonists
Key Highlights
Spironolactone shows extensive safety profile with unique adverse events. Eplerenone presents a concentrated safety profile with serious cardiac and renal incidents. Finerenone exhibits a specific profile primarily related to renal and metabolic areas. Hyperkalemia is a consistent signal across all three agents. Network toxicology assessment supports findings on drug-specific molecular targets. Guideline-Based Recommendations
Diagnosis
Utilize FAERS database for adverse event signal detection. Management
Individualized safety surveillance and monitoring of adverse events. Monitoring & Follow-up
Meticulous monitoring of adverse events in real-world settings. Risks
Consider potential for congenital malformations and severe cutaneous reactions with spironolactone. Patient & Prescribing Data
Patients with hypertension, heart failure, and chronic kidney disease.
Eplerenone may reduce sexual side effects compared to spironolactone.
Clinical Best Practices
Employ signal detection methodologies for assessing drug safety. Ensure optimal drug utilization to enhance patient benefits while minimizing risks. Related Resources & Content
